

Alain Delmer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3080025/alain-delmer-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

118 papers	4,656 citations	32 h-index	66 g-index
125 ext. papers	5,446 ext. citations	5.7 avg, IF	4.57 L-index

#	Paper	IF	Citations
118	Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).. <i>British Journal of Haematology</i> , 2022 ,	4.5	0
117	Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2021 ,	7.8	6
116	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. <i>Haematologica</i> , 2021 , 106, 2940-2946	6.6	4
115	A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. <i>Blood</i> , 2021 , 137, 2646-2656	2.2	10
114	A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. <i>Blood</i> , 2021 , 137, 1019-1023	2.2	1
113	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021 , 35, 1597-1609	10.7	3
112	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. <i>Blood Advances</i> , 2021 , 5, 539-548	7.8	6
111	Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. <i>Leukemia</i> , 2021 , 35, 2332-2345	10.7	0
110	Watch and wait in Waldenström macroglobulinaemia: looking for who to watch carefully and who can wait without worrying. Is it that simple?. <i>British Journal of Haematology</i> , 2021 , 195, 155-157	4.5	0
109	Frontline treatment in CLL: the case for time-limited treatment. <i>Hematology American Society of Hematology Education Program</i> , 2021 , 2021, 59-67	3.1	0
108	Autoimmune haemolytic anaemia associated with COVID-19 infection. <i>British Journal of Haematology</i> , 2020 , 190, 29-31	4.5	165
107	Hypercalcemia at diagnosis of diffuse large B-cell lymphoma is not uncommon and is associated with high-risk features and a short diagnosis-to-treatment interval. <i>Hematological Oncology</i> , 2020 , 38, 326-333	1.3	1
106	Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. <i>Haematologica</i> , 2020 , 105, 1379-1390	6.6	7
105	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020 , 95, 274-281	7.1	18
104	Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO). <i>HemaSphere</i> , 2020 , 4, e473	0.3	9
103	Early F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 649-654	8.9	25
102	Performance of CT Compared with F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma. <i>Radiology</i> , 2020 , 295, 651-661	20.5	17

101	Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogeneic stem cell transplantation. <i>European Journal of Cancer</i> , 2019 , 115, 47-56	7.5	22
100	Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group. <i>American Journal of Hematology</i> , 2019 , 94, E183-E185	7.1	7
99	Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 823-833	2.2	92
98	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology, the</i> , 2019 , 6, e470-e479	14.6	14
97	Prevalence of and mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. <i>Blood</i> , 2019 , 134, 641-644	2.2	53
96	Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies. <i>Haematologica</i> , 2019 , 104, e360-e363	6.6	21
95	Difficult Gram staining: a case of endocarditis due to <i>Cardiobacterium hominis</i> and review of the literature. <i>Annales De Biologie Clinique</i> , 2019 , 77, 549-556	0.4	
94	Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1563-1567	1.9	
93	PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology, The</i> , 2019 , 20, 202-215	21.7	86
92	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018 , 132, 49-58	2.2	90
91	Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2018 , 103, e304-e306	6.6	2
90	Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. <i>Lancet Haematology, the</i> , 2018 , 5, e82-e94	14.6	15
89	Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study. <i>Haematologica</i> , 2018 , 103, e356-e359	6.6	5
88	Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation. <i>British Journal of Haematology</i> , 2018 , 182, 148-152	4.5	3
87	Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1614-1623	1.9	11
86	A neutrophil "Ugly Duckling". <i>British Journal of Haematology</i> , 2018 , 183, 701	4.5	
85	Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO). <i>American Journal of Hematology</i> , 2018 , 93, E52-E54	7.1	1
84	Skeletal involvement of hairy cell leukemia. <i>Clinical Case Reports (discontinued)</i> , 2018 , 6, 1651-1652	0.7	4

83	Pulmonary adverse events related to idelalisib therapy: A single centre experience. <i>Journal of Chemotherapy</i> , 2018 , 30, 318-322	2.3	4
82	Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2017 , 176, 997-999	4.5	5
81	Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1366-1375	1.9	5
80	Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. <i>American Journal of Hematology</i> , 2017 , 92, E105-E107	7.1	8
79	Prognostic factors associated with 30-day in-hospital mortality in coagulase-negative Staphylococcus bacteraemia: no impact of vancomycin minimum inhibitory concentration. <i>Infectious Diseases</i> , 2017 , 49, 664-673	3.1	1
78	Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report. <i>Medicine (United States)</i> , 2017 , 96, e6403	1.8	2
77	Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). <i>British Journal of Haematology</i> , 2017 , 179, 439-448	4.5	24
76	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 635-647	6.2	16
75	The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. <i>Oncotarget</i> , 2017 , 8, 8765-8774	7.3	42
74	Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , 2016 , 91, 782-6	7.1	20
73	Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 328-334	1.9	8
72	Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study. <i>American Journal of Hematology</i> , 2016 , 91, 410-5	7.1	4
71	Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. <i>Lancet Haematology</i> , 2016 , 3, e128-38	14.6	28
70	Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1001-9	3.8	26
69	Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). <i>American Journal of Hematology</i> , 2015 , 90, 204-7	7.1	29
68	Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients. <i>American Journal of Hematology</i> , 2015 , 90, E5-8	7.1	17
67	Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience. <i>American Journal of Hematology</i> , 2015 , 90, 511-4	7.1	21
66	Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study. <i>European Journal of Haematology</i> , 2015 , 95, 160-7	3.8	17

65	Diagnosis approach of chronic lymphocytic leukemia on unstained blood smears using Raman microspectroscopy and supervised classification. <i>Analyst, The</i> , 2015 , 140, 4465-72	5	12
64	Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases. <i>Annals of Hematology</i> , 2015 , 94, 89-95	3	16
63	Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1905-11	4.7	12
62	2014 SFH guidelines for diagnosis and management of hairy cell leukemia. <i>Hematologie</i> , 2014 , 20, 200-206		
61	Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. <i>Annals of Hematology</i> , 2014 , 93, 1977-83	3	36
60	Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA. <i>Lymphoma</i> , 2014 , 2014, 1-12		11
59	Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in Ultra High-risk CLL: Final Results from the CLL2O Phase II Study. <i>Blood</i> , 2014 , 124, 1991-1991	2.2	10
58	Results of a Phase II Randomizing Intensified Rituximab Pre-Phase Followed By Standard FCR Vs Standard FCR in Previously Untreated Patients with Active B-Chronic Lymphocytic Leukemia (B-CLL). CLL2010FMP (For fit medically patients): A Study of the french Cooperative Group on CLL and T1M (FCGCLL/T1M) and the Groupe Ouest-Est d'Etudes Des Leucémies Aigües Et Autres	2.2	3
57	High Resolution Genomic Profiling of Primary Ultra High Risk and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. <i>Blood</i> , 2014 , 124, 3288-3288	2.2	
56	Genomic Mechanisms of 17p / TP53 Loss in Primary Ultra High-risk and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. <i>Blood</i> , 2014 , 124, 2184-2184	2.2	
55	Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study. <i>Blood</i> , 2014 , 124, 4430-4430	2.2	
54	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013 , 14, 525-33	21.7	200
53	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. <i>Blood</i> , 2013 , 121, 48-53	3.2	197
52	An aggressive B-cell lymphoma with rearrangements of MYC and CCND1 genes: a rare subtype of double-hit lymphoma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 649-52	1.9	7
51	2012 SFH Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukemia (CLL). <i>Hematologie</i> , 2013 , 19, 4-9	0	
50	Management of elderly patients with chronic lymphocytic leukemia. <i>Hematologie</i> , 2013 , 19, 10-20	0	
49	Specific treatment modalities for elderly patients with chronic lymphocytic leukemia. <i>Aging Health</i> , 2012 , 8, 317-322		1
48	Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. <i>Blood</i> , 2012 , 119, 5104-10	2.2	72

47	Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. <i>Blood</i> , 2012 , 120, 2650-7	2.2	47
46	Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. <i>Haematologica</i> , 2012 , 97, 1594-602	6.6	58
45	Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. <i>Haematologica</i> , 2012 , 97, 213-8	6.6	35
44	Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. <i>Lancet, The</i> , 2011 , 377, 42-51	40	806
43	TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. <i>Haematologica</i> , 2011 , 96, 1059-63	6.6	26
42	Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience. <i>Leukemia Research</i> , 2011 , 35, 1444-8	2.7	29
41	Binucleated lymphocytes in patients with multiple sclerosis treated with natalizumab. <i>Leukemia and Lymphoma</i> , 2011 , 52, 910-2	1.9	10
40	Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prirituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. <i>Journal of Clinical Oncology</i> , 2010 , 28, 822-9	2.2	60
39	Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 2010 , 363, 2511-21	59.2	304
38	Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. <i>Molecular Cancer</i> , 2010 , 9, 115	42.1	61
37	Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. <i>Cancer</i> , 2010 , 116, 631-9	6.4	134
36	IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. <i>Annals of Hematology</i> , 2009 , 88, 1215-21	3	23
35	High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2008 , 143, 54-9	4.5	17
34	Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , 2008 , 111, 4463-70	2.2	237
33	Gastro-intestinal lymphomas. <i>Gastroenterologie Clinique Et Biologique</i> , 2006 , 30, 81-90		1
32	Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. <i>Blood</i> , 2006 , 108, 4163-9	2.2	103
31	Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. <i>Blood</i> , 2005 , 105, 767-74	2.2	66
30	A new acute lymphoblastic leukaemia cell line BEL-1 with t(4; 11) (q21; q23) chromosomal translocation and a unique aberrant p27 transcript. <i>British Journal of Haematology</i> , 2004 , 126, 754-5	4.5	4

29	CD10 expression in diffuse large B-cell lymphomas does not influence survival. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004 , 445, 545-51	5.1	26
28	FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. <i>British Journal of Haematology</i> , 2004 , 124, 55-62	4.5	23
27	Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2004 , 103, 363-5	2.2	97
26	Visceral larva migrans mimicking lymphoma. <i>Chest</i> , 2003 , 123, 1296-7	5.3	16
25	Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. <i>British Journal of Haematology</i> , 2003 , 122, 404-12	4.5	51
24	Primary plasma cell leukaemia: a report of 18 cases. <i>Leukemia Research</i> , 2001 , 25, 103-7	2.7	69
23	Splenic marginal zone lymphoma with or without plasmacytic differentiation. <i>American Journal of Surgical Pathology</i> , 2000 , 24, 1581-92	6.7	61
22	Molecular epidemiology of human herpesvirus 8 in africa: both B and A5 K1 genotypes, as well as the M and P genotypes of K14.1/K15 loci, are frequent and widespread. <i>Virology</i> , 2000 , 278, 60-74	3.6	75
21	Mantle cell lymphoma, in leukaemic phase with prominent splenomegaly. A report of eight cases with similar clinical presentation and aggressive outcome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000 , 437, 591-8	5.1	19
20	Immune thrombocytopenic purpura as the presenting feature of gastric MALT lymphoma. <i>American Journal of Gastroenterology</i> , 2000 , 95, 1599-600	0.7	10
19	Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. <i>Leukemia and Lymphoma</i> , 1999 , 32, 545-52	1.9	104
18	Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients. <i>Supportive Care in Cancer</i> , 1999 , 7, 89-94	3.9	16
17	Pentasomy 13q in a case of acute myelogenous leukemia (Mo). <i>Cancer Genetics and Cytogenetics</i> , 1998 , 107, 73-5		2
16	Homing receptor alpha4beta7 integrin expression predicts digestive tract involvement in mantle cell lymphoma. <i>American Journal of Pathology</i> , 1998 , 153, 1701-5	5.8	37
15	Prognostic Significance of the Cell Cycle Inhibitor p27Kip1 in Chronic B-Cell Lymphocytic Leukemia. <i>Blood</i> , 1998 , 91, 4694-4700	2.2	128
14	Idiopathic thrombocytopenic purpura as the presenting feature of a primary bilateral adrenal non Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 1997 , 26, 609-13	1.9	12
13	Treatment of hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine (2-CdA): identification of parameters predictive of adverse effects. <i>British Journal of Haematology</i> , 1997 , 99, 165-7	4.5	9
12	Scleritis and mucosal-associated lymphoid tissue lymphoma: a new masquerade syndrome. <i>Ophthalmology</i> , 1996 , 103, 631-5	7.3	46

11	Over-expression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13. <i>British Journal of Haematology</i> , 1995 , 89, 798-804	4.5	29
10	Another case of trisomy 4 with double minute chromosomes in acute non-lymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1995 , 83, 165-7		6
9	Acute colonic pseudo-obstruction (Ogilvie's syndrome) during induction treatment with chemotherapy and all-trans-retinoic acid for acute promyelocytic leukemia. <i>American Journal of Hematology</i> , 1995 , 49, 97-8	7.1	5
8	Expression of resistance genes in acute leukemia. <i>Leukemia and Lymphoma</i> , 1994 , 13 Suppl 1, 27-30	1.9	9
7	Spontaneous remission in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1994 , 87, 880-2	4.5	26
6	Acute myelomonocytic leukemia in a XYY man. <i>Cancer Genetics and Cytogenetics</i> , 1993 , 69, 156-7		5
5	In vitro effect of rGM-CSF on proliferation and maturation of leukemic cells from patients with acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 1993 , 11, 99-104	1.9	4
4	Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity. <i>Leukemia and Lymphoma</i> , 1993 , 10, 67-71	1.9	6
3	Primary digestive tract lymphoma: a prospective multicentric study of 91 patients. Groupe d'Etude des Lymphomes Digestifs. <i>Gastroenterology</i> , 1993 , 105, 1662-71	13.3	140
2	Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia. <i>British Journal of Haematology</i> , 1992 , 82, 783-4	4.5	39
1	Peripheral T-cell lymphoma presenting as hypereosinophilia with vasculitis. <i>American Journal of Medicine</i> , 1988 , 84, 565-6	2.4	5